19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
21:03 , Jan 30, 2019 |  BC Innovations  |  Translation in Brief

Epigenetic links in endometriosis

An HDAC3-mediated epigenetic pathway could lead to new therapies and markers for endometriosis and associated infertility. Researchers from Michigan State University and Yonsei University College of Medicine have linked an epigenetic pathway involving HDAC3 to...
18:51 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting HDAC3 could help treat AD. In a HEK cell line expressing mutant APP, a tool compound HDAC3 inhibitor decreased levels of neurotoxic β amyloid...
23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) In vitro , cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC. Chemical synthesis and in vitro testing of conjugates consisting of...
16:50 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neuropathy Mouse studies suggest inhibiting HDAC3 could help treat peripheral neuropathies. In a mouse model of sciatic nerve injury, tool compound HDAC3 inhibitors increased the number of myelin-producing Schwann cells at the injury site...
16:45 , Feb 12, 2018 |  BC Extra  |  Preclinical News

HDAC3 inhibition promotes peripheral remyelination

A study published in Nature Medicine identified histone deacetylase 3 (HDAC3) as a target for boosting remyelination in peripheral neuropathies. Following demyelination in a mouse model of sciatic nerve injury, researchers from Cincinnati Children’s Hospital...
16:05 , Jun 27, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method of Cas9 -guided histone deacetylation could be used as gene therapy to promote or repress the expression of target genes. The method involves transfecting cells with two lentiviral vectors: one...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies identified a dual PDE-5 / HDAC inhibitor that could help treat AD. Chemical synthesis and in vitro testing of molecules that combined structural features of known...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies identified a dual PDE-5 / HDAC inhibitor that could help treat AD. Chemical synthesis and in vitro testing of molecules that combined structural features of known...
07:00 , Apr 14, 2016 |  BC Innovations  |  Product R&D

Clearing the RaNAway

Karen Tkach, Staff Writer  After launching RaNA Therapeutics Inc. in 2011 to exploit the therapeutic potential of long-noncoding RNA (lncRNA), the company has gone where the science led it, and added a second platform that...